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Introduction
▼The two-hybrid system (THS), first introduced by Fields
and Song (1989) (Ref. 1), is a powerful technique for identi-
fying new proteins involved in specific biological processes.
It allows for the rapid isolation of the gene that codes for
a protein that interacts with a specific protein of interest.
Here, we present not a review of the current THS technol-
ogy but, rather, a comprehensive guide designed to take
the reader through a THS screen. Readers not familiar with
the THS are asked to review (Ref. 1, 2, 3, 4, 5). Currently,
there are a number of different versions of the THS avail-
able. This article describes procedures useful for the ‘Fields’
THS, based on the GAL4 transcription factor. Many of the
following protocols can be used with other versions with
some modification; however, they might not be directly
applicable to the Brent Interaction Trap version because of
some distinct differences (Ref. 6).
This article (part A) is the first of three parts and describes
the preparation for a screen; part B describes the screen
itself and part C describes the analysis of the THS posi-
tives. If beginning a two-hybrid screen with an untested
bait gene, start with part A to test the bait plasmid and
yeast strain combination (see Figure 1 for a flow chart).
This plasmid–strain combination can be used to screen a
variety of libraries following the steps outlined in part B.
Part C is then used to characterize THS positives.
A1: Construction of the GAL4BD:bait gene fusion
plasmid
The first step is to construct the GAL4BD:bait gene fusion
plasmid (BD, binding domain). ‘Your Favorite Gene’ (YFG)
encoding the protein of interest (considered the bait) is
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cloned into a suitable THS vector in-frame with the GAL4BD
(amino acids 1–147). Table 1 and Figures 2, 3, 4 and 5 show
a list of THS vectors that include the GAL4BD vectors for
making the BD:bait fusion plasmid.
A1.1: Cloning strategies
There are a number of different cloning strategies that can
be used to clone YFG into aGAL4BD vector (see Table 2). The
first two strategies use compatible restriction sites found
in the bait gene and the multi-cloning site (MCS) of the
GAL4BD vector (see Figures 6a and 6b). For the blunt-end
ligation strategy (see Figure 6c) each GAL4BD vector listed
has a number of different options to allow the cloning into
each frame.
If YFG has identifiable protein domains or motifs these
can be fused to the GAL4BD for independent study. How-
ever, for uncharacterized proteins it is advisable to use as
much of the open reading frame (ORF) as possible to create
your fusion. The most important aspect of this cloning is
to ensure that YFG is in-frame with the GAL4BD, so that a
fusion protein can be produced. Therefore, we recommend
that your cloning strategy is checked by a knowledgeable
colleague. Finally, the fusion junction of any plasmid con-
structed should be sequenced before performing any screen
to confirm the ORF fusion. The GAL4BD sequencing primer,
5′-TCA TCG GAA GAG AGT AG-3′, can be used for GAL4BD
vectors such as pGBT9, pAS1 and pAS2.
Tips
Some vectors, such as pAS1 and pAS2, contain the
haemagluttinin (HA) tag, which allows immunological
detection of the fusion protein with the 12CA5 mono-
clonal antibody (Pharmacia) or equivalent monoclonal
antibody (Babco), see below.
The ATG codon of YFG does not have to be present in your
fusion construct. Translation is initiated at the start
codon of the GAL4BD.
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FIGURE 1. Two-hybrid system flow chart displaying the steps required for a THS screen. Begin at part A for preparation of the library, bait gene and
yeast strain. The constructed BD:bait plasmid/yeast strain can then be used in part B to screen a variety of AD:cDNA libraries. Part C lists the steps
involved in the characterization of putative THS positives. If less than 20 putative positives are obtained from part B, proceed through parts C1 to C5.
When more than 20 putative positives are obtained from part B, or when non-typical THS positives are encountered, begin with part C9: segregation
analysis, then proceed to analyze true positives employing the protocols outlined in parts C1 to C5. Part A refers to the protocol described in Ref. 19 and
Part C refers to that described in Ref. 20.
If cloning any portion of the 5′ untranslated region of a
gene into a GAL4BD vector, ensure that there are no
in-frame stop codons.
Ensure that cloning the bait gene into the vector does not
create an in-frame stop codon, especially if blunt-end
ligation was used.
A.2: Choosing the right THS reporter strain
There are many reporter yeast strains now available for
the ‘Fields’ THS. These strains vary in their reporter con-
structs. The ‘second generation’ of THS reporter strains usu-
ally includes both the lacZ and the HIS3 reporter genes. The
HIS3 reporter allows the direct selection of THS positives,
however, some strains contain ‘leaky’ derivatives that re-
quire the addition of the chemical 3-amino triazole (3-AT)
Table 1. Two-hybrid system plasmid vectors
Plasmid GAL4 domain Restriction sites Selection marker Ref.
pAS1 GAL4BD NdeI SfiI/NcoI SmaI BamHI SalI TRP1 7
pAS2 GAL4BD NdeI SfiI/NcoI SmaI BamHI SalI TRP1 8
pGBT9 GAL4BD EcoRI SmaI BamHI SalI PstI TRP1 9
pACT GAL4AD BglII EcoRI BamHI XhoI BglII LEU2 7
pACT2 GAL4AD NdeI SfiI/NcoI SmaI BamHI EcoRI SacI XhoI BglII LEU2 8
pGAD10 GAL4AD BglII XhoI BamHI EcoRI BglII LEU2 9
pGAD424 GAL4AD BglII EcoRI SmaI BamHI SalI PstI BglII LEU2 9
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FIGURE 2. Plasmid maps of two-hybrid system plasmids—DNA
GAL4-binding domain plasmids: pGBT9 (Ref. 9). The plasmid contains
the GAL4 DNA-binding domain (GAL4BD 1–147aa) bounded by the
constituitively expressing yeast alcohol dehydrogenase 1 promoter
(PADH1) and terminator (TADH1). The multi-cloning site is listed to
indicate the frame of the GAL4BD. All plasmids contain the yeast TRP1
gene, which allows for selection. Useful restriction sites are listed.
to the medium to quench background expression of the
HIS3 gene product (Ref. 7). The HIS3 reporter gene also se-
lects for the optimal ratios of fusion proteins to produce
reporter-gene expression for growth on selective medium
(Ref. 10). The lacZ reporter can be used to verify positives
through co-expression as well as to generate quantitative
measurements of gene expression.
Another important quality of a THS yeast strain is its
transformation characteristics. The ability to generate large
numbers of transformants using current transformation
protocols is essential for THS screening (Ref. 11). The strains
listed in Table 3 all have good transformation characteris-
tics. In addition, PJ69-4a and KGY37 contain reporter genes
that are integrated into their genomes, ensuring their main-
tenance in the absence of selection. Finally, the reporter
genes in KGY37 were constructed to produce low levels of
basal activity.
A.3: Testing the BD:bait plasmid for auto-activation
It is important to test each BD:bait plasmid construct for
auto-activation of both reporter genes before any screen.
The activation of reporter genes by the BD:bait plasmid
in the absence of an activation-domain plasmid is defined
as auto-activation. Transform the BD:bait plasmid into the
appropriate reporter yeast strain using the ‘Quick and Easy’
transformation technique described in Ref. 11, then pro-
ceed to test both reporter genes for auto-activation as out-
lined below.
A.3.1: GAL1-HIS3 reporter gene
To test for auto-activation of the GAL1-HIS3 reporter, yeast
cells containing the BD:bait plasmid should be plated, not
streaked, onto synthetic complete, minus histidine (SC-H)
medium containing increasing concentrations of 3-AT (1,
5, 10, 25 and 50 mM). In addition, these yeast cells should
be plated onto synthetic complete, minus tryptophan (SC-
W) medium to select for the BD:bait plasmid as a control of
growth. 3-AT is used in the medium to suppress the ‘leaky’
nature of this reporter in most strains. The concentration
of 3-AT needed to eliminate background growth is plasmid
and strain dependent. We have found that when screening
pAS1 or pAS2 BD:bait plasmid constructs, or when using
the strain Y190, higher levels of 3-AT might be required to
suppress background GAL1-HIS3 expression.
Protocol
Grow your yeast transformant containing the verified
BD:bait plasmid overnight in SC-W medium to select
for maintenance of the GAL4BD plasmid. Alternatively,
a 10 µl blob of cells can be scraped from a freshly grown
SC-W plate and resuspended in 1 ml of sterile water.
Titer the liquid culture using a spectrophotometer (OD600
0.1=∼1×106 cells/ml) or a hemocytometer.
Plate at least 1000 cells/plate onto a pair of SC-W plates as
well as pairs of SC-H plates containing 0, 1, 5, 10, 25
and 50 mM 3-AT.
Incubate at 30◦C for 5 days.
Examine the SC-H +3-AT plates for growth. Most BD:bait
plasmids will not produce colonies on the medium once
the appropriate concentration of 3-AT is reached. The SC-W
control plates should contain approximately 1000 colonies.
If you cannot inhibit all growth on SC-H + 3-AT, even at
a 50 mM concentration, consider either cloning a different
gene fragment into your BD:bait plasmid, or cloning YFG
into another GAL4BD vector.
Tip
Auto-activation by the BD:bait construct does not necessar-
ilymean the end of your screen. Cloning your bait gene
into a different vector, such as pGBT9,might reduce the
auto-activation if pAS1 or pAS2 were used previously.
Alternatively, the construct can be modified by dele-
tion to remove the region responsible for the auto-
activation. Another option reduces auto-activation by
‘dampening’ (Ref. 14).
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FIGURE 3. Plasmid maps of two-hybrid system plasmids—DNA GAL4-binding domain plasmids: pAS1 (Ref. 7) and pAS2 (Ref. 8). Both plasmids contain
the GAL4 DNA-binding domain (GAL4BD 1–147aa) bounded by the constituitively expressing yeast alcohol dehydrogenase 1 promoter (PADH1) and
terminator (TADH1). The multi-cloning site is listed to indicate the frame of the GAL4BD. All plasmids contain the yeast TRP1 gene, which allows for
selection. The CYH2 gene found in pAS2 confers sensitivity to cycloheximide in the strain Y190 (see Table 3). pAS1 and pAS2 contain the DNA sequence
encoding the hemagluttinin tag (HA) fused to the GAL4BD open reading frame. Useful restriction sites are listed.
A.3.2: GAL1-lacZ reporter gene
In addition to testing for GAL1-HIS3 auto-activation it is
also prudent to test for GAL1-lacZ auto-activation in those
strains that contain this reporter gene. This can be accom-
plished following the protocol listed below. You can use
the pair of SC-W plates that were plated for the GAL1-HIS3
auto-activation test above.
Protocol
Carefully place a sterile 75 mm circle of Whatman No. 1
filter paper on top of the colonies or patches growing
on selective medium. Ensure that the filter paper makes
good contact with the colonies. Mark the orientation of
the filter paper relative to the plate using an 18-gauge
needle to punch through the filter in an asymmetric
pattern.
Remove the filter from the plate with sterile forceps after it
has become fully absorbed to the colonies and immerse
in liquid nitrogen for 10 to 15 s.
Carefully remove the filter from the liquid nitrogen and
thaw by placing on a piece of plastic wrap colony side
up. Repeat the freeze-thaw cycle twice.
Place another 75 mm sterile Whatman No. 1 filter into an
empty Petri plate (100×150 mm) and dispense 1.25 ml
of Z buffer/β-mercaptoethanol/X-GAL (see A) onto the
filter.
Place the filter colony side up, onto a filter paper soaked
with Z buffer/β-mercaptoethanol/X-GAL, taking care
that the filters line up to distribute the solution evenly.
Place the lid on each plate and transfer to a plastic bag and
incubate at 37◦C.
Strong activation of the lacZ gene will give a blue color
within 1–2 h. If color does not develop, continue to incu-
bate the filters overnight. Note the time needed for color
production. A faint blue color after overnight incubation is
considered minimal lacZ activation.
A.4: Expression of your fusion protein
Before screening we recommend that the steady state ex-
pression of the BD:bait fusion protein is assayed by west-
ern blotting. This can be accomplished if the appropriate
reagents are available, such as a specific antibody for the
product of YFG. Some vectors, such as pAS1 and pAS2, con-
tain the haemagluttinin (HA) tag (Ref. 15), which can be rec-
ognized by the commercially available 12CA5 monoclonal
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FIGURE 4. Plasmid maps of two-hybrid system plasmids—activation-domain plasmids: pGAD10 (Ref. 9) and pGAD424 (Ref. 9). Each plasmid contains
the GAL4 transcription activating domain (GAL4AD 768–881) bounded by the constituitively expressing yeast alcohol dehydrogenase 1 promoter (PADH1)
and terminator (TADH1). The multi-cloning site is listed to indicate the frame of the GAL4BD. All plasmids contain the yeast LEU2 gene, which allows for
selection. All plasmids contain the yeast 2 micron circle origin of replication (2 µ ori), an Escherichia coli plasmid replication origin (ori) and the β-lactamase
gene responsible for ampicillin resistance (ApR). The direction of transcription is indicated by an arrow within each gene. Useful restriction sites are listed.
antibody (Pharmacia) or equivalent monoclonal antibody
(Babco). The Gal4BD antibody (Santa Cruz Biotechnology
Inc.) can also be used. In addition to indicating the expres-
sion levels of the fusion protein, western blotting can verify
the in-frame cloning strategy, because the size of the fusion
protein detected should be comparable with the predicted
value.
Protocol
Yeast lysates are prepared for electrophoresis following a
modified method of Rocchi et al. (Ref. 16).
Inoculate the yeast strain containing the BD:bait plasmid
into 50 ml of SC-W medium. Incubate at 30◦C with
shaking until a titer of 1.0×107 cells/ml is reached. This
might take 16–24 h. Alternatively, a 10 ml overnight
culture can be used to inoculate 50 ml to 2.5×106
cells/ml and incubate until a titer of 1–2×107 cells/ml
is reached. This will take 4–6 h in SC-W medium.
Collect the yeast cells by centrifugation at 5000×g for 5min
and wash the cells with a 0.5 volume of sterile water.
Determine the volume of the cell pellet by adding a
specific volume of water and then measuring the total
volume of the cell slurry.
Resuspend the cells in two volumes of ice-cold extraction
buffer (see A).
Add one volume of glass beads (Sigma, Catalogue no.
G-8772) and place each sample on ice.
Vortex each sample vigorously for 30 s and return to ice to
cool. Repeat six times for each sample.
Centrifuge samples at 14 000×g at 4◦C for 1 min to pellet
unbroken cells and cell debris.
Transfer the supernatant to another 1.5 ml microcentrifuge
tube and cool each sample in an ice slurry for 1 min.
Centrifuge each sample again at 14 000×g at 4◦C for 1 min
to further clarify the extract.
Carefully remove supernatant and mix 1:1 with SDS load-
ing buffer (see A) and heat in a boiling water bath for
2 min. Protein extracts can be stored at −70◦C until
needed.
A.5: Amplifying the AD:cDNA library
A library screen can consume up to 300 µg of plasmid DNA
depending on the yeast strain and BD:bait plasmid. Thus,
it might be necessary to transform and/or amplify your
AD:cDNA plasmid library. A list of libraries can be found
in Ref. 17; however, many AD:cDNA libraries are currently
available commercially from companies that include Clon-
Tech Laboratories Inc., InVitrogen and Stratagene.
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FIGURE 5. Plasmid maps of two-hybrid system plasmids—activation-domain plasmids: pACT (Ref. 7) and pACT2 (Ref. 8). Each plasmid contains the
GAL4 transcription activating domain (GAL4AD 768–881) bounded by the constituitively expressing yeast alcohol dehydrogenase 1 promoter (PADH1) and
terminator (TADH1). The multi-cloning site is listed to indicate the frame of the GAL4BD. All plasmids contain the yeast LEU2 gene, which allows for
selection. The plasmid pACT2 contains the DNA sequence encoding the hemagluttinin tag (HA) fused to the GAL4AD open reading frame. All plasmids
contain the yeast 2 micron circle origin of replication (2 µ ori), an Escherichia coli plasmid replication origin (ori) and the β-lactamase gene responsible for
ampicillin resistance (ApR). The direction of transcription is indicated by an arrow within each gene. Useful restriction sites are listed.
In order to amplify all clones within a library
most efficiently, transformed bacterial cells are grown
on plates to allow individual colonies to form. We
typically plate about 10 times the library complexity
for amplification. Most AD:cDNA libraries have com-
plexities of 1–2×106 independent clones; therefore, for
good library coverage, 10–20×106colonies should be
amplified.
Protocol
Prepare 100 large (150 mm) Petri plates containing the ap-
propriate medium [Lauria Bertani (LB) + ampicillin at 50
mg/ml]. Also, prepare 500 ml sterile saline solution (150
mM NaCl), to be used to resuspend the bacterial colonies.
Library plasmid DNA should be transformed into a suitable
strain of Escherichia coli.
Titer the E. coli library culture by plating 2, 20 and 200 µl
of a 10−2 dilution onto duplicate LB + Amp (50 µg/ml)
plates (100 mm) and incubate overnight at 37◦C. Store
remaining culture at 4◦C.
Plate 2×105 cells of library culture onto each large (150
mm) LB + Amp plate and incubate until the colonies
are fully formed (usually 16–24 h).
Harvest the bacterial colonies by flooding a plate with
10 ml of sterile saline and scraping the colonies from
the agar surface using a rubber policeman or bent glass
rod. Be careful not to damage the agar while harvest-
ing bacteria. When complete, dump the liquid onto
another plate and repeat. Each 10 ml aliquot can be
used for up to 5 plates. After the solution is saturated
with bacteria, transfer to a centrifuge tube. Start the
Table 2. BD:bait plasmid cloning strategies
1 PCR amplification of YFG ORF placing unique GAL4BD vector restriction sites 5′ and 3′ to construct the BD:bait plasmid. See Figure 3a
2 Using existing GAL4BD vector MCS restriction sites within YFG ORF to construct the BD:bait plasmid. See Figure 3b
3 Blunt-end ligate a restriction fragment containing YFG ORF into the appropriate frame to construct the BD:bait plasmid. See Figure 3c
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FIGURE 6. Cloning strategies for the GAL4BD:bait fusion. (a) PCR modify your open reading frame (ORF). PCR primers are designed to amplify the ORF
of ‘your favourite gene’ (YFG) and place unique restriction site(s) in-frame at the 5′ and 3′ ends of the ORF, as indicated. The amplified ORF is then
digested with the desired restriction enzyme(s) and subsequently purified. The purified fragment is ligated into the multiple cloning site (MCS) of pGBT9.
A number of clones should be fully sequenced to confirm that mutations have not been produced in your amplified ORF. (b) Natural restriction sites.
Restriction sites that naturally occur in YFG can be used to clone it into the MCS of your GAL4BD vector. Note that the NcoI site in the YFG ORF has the
same frame as the NcoI site in the MCS of the vector. This example uses a naturally occurring BamHI site in the 3′ untranscribed region of YFG.
Alternatively, a single restriction enzyme can be used. Both the YFG DNA fragment and the GAL4BD vector are double digested with NcoI, BamHI and
purified. The vector is treated with calf intestinal alkaline phophatase (Boehringer-Mannheim) to reduce self-ligation. (c) Blunt-end ligation. Most
restriction fragments containing 5′ overhangs can usually be cloned in-frame, by blunt-end ligation, into the GAL4BD vectors listed in Table 1. Note that
the NcoI site at the 5′ end of the YFG ORF has a different frame than the NcoI site in the MCS of the pAS2 vector. To produce an in-frame gene fusion, the
XmaI site in the vector is digested and the resulting 5′ overhang filled in with Klenow polymerase. The ends of the NcoI–BamHI DNA fragment are also
filled in with Klenow polymerase, followed by ligation into the blunted XmaI digested pAS2 vector. This will generate the correct frame for gene fusion.
Note that both the XmaI and NdeI sites in the MCS of the GAL4BD vectors listed require two base pairs to restore frame. The NcoI, BamHI, and SalI sites
in these GAL4BD vectors do not require any base pairs to maintain frame, while the SmaI site requires one base pair to restore frame.
next set of plates with a fresh 10 ml of sterile saline.
Repeat until all the plates have been scraped.
Mix all aliquots of bacteria together then distribute into six
50 ml centrifuge tubes. Collect the cells by centrifuga-
tion at 10 000 rpm for 10 min.
Proceed to plasmid DNA extraction as described in Ref. 18.
This procedure will give good amplification of your
AD:cDNA library. There is no need to purify the plasmid
from the endogenous RNA because it does not affect yeast
transformation (R.D. Gietz et al., unpublished). You are now
ready to begin your screen.
Tips
Completely resuspend the bacterial pellets before adding
the SDS:NaOH reagent to ensure good lysis.
A single phenol:chloroform extraction produces good-
quality plasmid DNA for transformation into yeast.
Use molecular biology grade phenol or distill your own!
An exact DNA concentration is not important because a
library efficiency test is performed before screening.
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Table 3. Two-hybrid yeast strains
Yeast strain Genotype Reporter genes Plasmid selection Ref .
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Appendix A. Media
Yeast extract–peptone–dextrose medium + adenine (YPAD)
Yeast extract 6 g
Peptone 12 g
Glucose 12 g
Adenine hemi-sulphate 24 mg (liquid), 48 mg (plates)
Distilled water 600 ml
Difco Bacto-agar 10 g (plates)
Sterilize by autoclaving at 121◦C for 20 min. We make 600
ml ofmedia in a 1 l flask as it is easier to handle for pour-




Yeast extract 3 g
NaCl 6 g
Distilled water 600 ml
Titrate to pH 7.0 with 10N NaOH
For plates: add 10 g Difco Bacto Agar to per 600 ml volume
in each flask prior to sterilization. When cooled, add
300 µl of a 100 mg/ml stock of ampicillin.
For liquid: do not add agar; ampicillin should be added just
prior to use.
Synthetic complete medium (SC)
Difco yeast nitrogen base (without amino acids) 4 g
Glucose 12 g
Synthetic complete selection medium mix 0.4 g
Distilled water 600 ml
Difco Bacto Agar 10 g (add for agar medium)
Add ingredients to water, mix and adjust the pH to 5.6–6.0
with NaOH; autoclave at 121◦C for 20 min.
Synthetic complete selection medium mix (SC medium)1
Supplement Amount Final concentration
Adenine hemisulfate 1.8 g 30 mg/l
Arginine HCl 1.2 g 20 mg/l
Histidine HCl 1.2 g 20 mg/l
Inositol 2.0 g 33 mg/l
Isoleucine 1.8 g 30 mg/l
Leucine 1.8 g 30 mg/l
Lysine HCl 1.8 g 30 mg/l
Methionine 1.2 g 20 mg/l
p-aminobenzoic acid 0.2 g 3 mg/l
Phenylalanine 3.0 g 50 mg/l
Homoserine 6.0 g 100 mg/l
Tryptophan 2.4 g 40 mg/l
Tyrosine 1.8 g 30 mg/l
Uracil 1.2 g 20 mg/l
Valine 9.0 g 150 mg/l
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1Omit the appropriate component(s), indicated in bold
type, to prepare SC-H, SC-L, SC-W, SC-W-L, and SC-
W-L-H.
Combine the ingredients in a clean 250 ml plastic bottle.
Add three or four clean glass marbles and shake vigor-
ously tomix. This quantity will be sufficient for approx-
imately 60 liters or 100×600ml batches of SCmedium.
M9 Minus Leucine prototrophy medium (M9-L)
10×M9 salts 60 ml
distilled water 540 ml
Difco Bacto-agar 10 g
Autoclave this, allow to cool until flask is warm to touch,
then add sterile:
MgSO4 (1.00 M) 0.60 ml
CaCl2 (0.10 M) 0.60 ml
Thiamine (4 mg/ml) 0.50 ml
Glucose (20% w/v) 6.00 ml
FeCl3 (0.01 M) 0.15 ml
Vitamin B1 (2 mg/ml) 0.60 ml
Depending on the geneticmarkers found in your Escherichia
coli strain, add the appropriate amino acids:
For KC8 add the following:
Histidine (2 mg/ml) 6 ml
Uracil (2 mg/ml) 6 ml
Tryptophan (2 mg/ml) 6 ml
Solutions




Titrate with 10 N NaOH to pH 7.0.
X-GAL (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside), 20
mg/ml
Dissolve 1.0 g of X-GAL in 50 ml of N,N-
dimethylformamide and store at −20◦C.
Z buffer/β-mercaptoethanol
This should be made fresh by adding 270 µl of β-
mercaptoethanol to 100 ml Z buffer.
Z buffer/β-mercaptoethanol/X-GAL
This should be made fresh by adding 270 µl of 2-
mercaptoethanol and 1.67 ml of X-GAL solution (20
mg/ml) to 100 ml of Z buffer.
ONPG (o-nitrophenyl-β-D-galacto-pyranoside), 4 mg/ml
Dissolve 200 mg of ONPG in 50 ml Z buffer.
Extraction buffer
50 mM HEPES pH 7.4
200 mM NaCl






2.5 µg/ml pepstatin A
1 mM phenylmethylsulfonyl fluoride (PMSF)
TBST Buffer
20 mM Tris-HCl pH 7.5
200 mM NaCl
0.1% Tween 20
Add 5% (w/v) skim milk powder just before use.
SDS-loading buffer
3% w/v sodium dodecyl sulfate
62.5 mM Tris pH 6.8
720 mM β-mercaptoethanol
10% v/v glycerol
0.125% (w/v) bromophenol blue
TE buffer
10 mM Tris-Cl pH 8.0
1 mM EDTA pH 8.0
Yeast lysis buffer
10 mM Tris-Cl pH 8.0
100 mM NaCl
1 mM EDTA
2% (v/v) Triton X-100
1% (w/v) sodium dodecyl sulfate (SDS)





Bring up to 1 l with distilled water and autoclave.
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Products Used
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Amersham Pharmacia Biotech
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Amersham Pharmacia Biotech
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Amersham Pharmacia Biotech
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Babco
monoclonal antibody: monoclonal antibody
from Amersham Pharmacia Biotech
glass beads: glass beads from Sigma
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